6月9日 - ** 癌症诊断公司 Grail GRAL.O 股价下跌 3% 至 37.16 美元
** Ningi Research表示看空Grail的股票，理由是该公司在癌症筛查方面 "过于雄心勃勃"，造成了 "难以逾越的监管障碍"。
** Ningi 在报告中说："我们认为，Grail 的癌症检测测试所依据的数据仅足以引起投资者的炒作，但还远远不足以说服专家、监管机构或保险公司相信其临床实用性。 (link)
** Ningi 称该公司的实际销售额 "大大低于预期"。
** GRAL 股价今年以来上涨了一倍多
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.